SORRENTO THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.012 USD | -11.11% |
|
-25.00% | -90.28% |
| Apr. 10 | Sorrento Therapeutics, Inc. Emerged from Bankruptcy | CI |
| Mar. 15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
Presenter SpeechBrian Cooley (Executives)Hello. Good morning, everyone. I'm Brian Cooley, Seni...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Companyâs segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Companyâs immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.
| 1st Jan change | Capi. | |
|---|---|---|
| -90.28% | 6.52M | |
| +5.50% | 111B | |
| +11.01% | 105B | |
| -12.26% | 22.34B | |
| -3.00% | 21.93B | |
| -6.13% | 18.59B | |
| -36.52% | 18.12B | |
| -9.51% | 16.96B | |
| +2.91% | 13.7B | |
| +37.46% | 12.45B |
- Stock Market
- Equities
- SRNE Stock
- News Sorrento Therapeutics, Inc.
- Transcript : Sorrento Therapeutics, Inc. - Special Call
